axelvento
3月前
New Drug Doubles One-Year Survival in Pancreatic Cancer Trial
Phase 2 randomized trial shows 38 percent reduction in risk of death with the drug when combined with chemotherapy
Devalingam Mahalingam, MBBChBAO, professor of Medicine in the division of Hematology and Oncology.
Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer, according to a study published in Nature Medicine.
In a randomized phase 2 clinical trial, patients who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone. The drug also reduced the risk of death by 38 percent.
The study is one of only a few successful randomized trials in the last decade to show a survival benefit that would be applicable to a broad population of pancreatic cancer patients, according to the authors. Pancreatic cancer is the third leading cause of cancer-related mortality in the U.S.
“Pancreatic cancer remains one of the most challenging solid tumors to treat, but these findings provide cautious optimism for patients,” said study lead author Devalingam Mahalingam, MBBChBAO, professor of Medicine in the Division of Hematology and Oncology.
“While these results will need to be confirmed in phase 3 trials, observing survival benefit in such a difficult-to-treat cancer is encouraging. Given the novel mechanism of this drug, these findings raise the possibility that it could have broader application across other tumor types,” added Mahalingam, who also is the associate director of clinical research at Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
How the trial was conducted
The phase 2 trial enrolled 233 patients with metastatic pancreatic cancer across 60 sites in six countries in North America and Europe. Patients were randomly assigned to receive either standard chemotherapy or the same chemotherapy combined with elraglusib.
Those who received elraglusib lived a median of 10.1 months, compared to 7.2 months for those who only received chemotherapy. While that three-month difference may appear modest, it’s partly because the trial included patients whose cancer progressed too quickly to benefit from treatment.
Among patients who benefited from the drug, the impact was pronounced. Twice as many patients who received elraglusib were alive at one year (44 percent vs. 22 percent) and about 13 percent of patients in the drug group were alive at two years, compared to none in the chemotherapy group.
Side effects were generally consistent with chemotherapy but slightly more common in the elraglusib group. The most frequent included low white blood cell counts, fatigue and temporary vision changes, which were reversible. Overall, the safety profile of the drug was considered manageable, the authors said in the study.
‘My husband believed in helping future patients’
Because the trial started more than five years ago in the U.S., most American participants have since died from their cancer. But relatives of two Northwestern Medicine patients who received the drug and lived for roughly two years after starting the trial said participating gave their loved ones a sense of purpose.
Donna Husar, 65, of Palos Heights, Illinois, said her late husband, Matthew, chose to participate shortly after his diagnosis in consultation with a relative who worked in oncology. “If you have any opportunity to go on a trial drug, go for it,” she recalled being told. Matthew Husar remained in the trial for nearly two years, and the family credits the drug with giving them more time together.
For his daughter, Madeline, 29, of Chicago, the clinical trial offered something to hold onto. “When you read about pancreatic cancer online, it’s terrifying,” she said. “But knowing there was research and a trial gave us something positive to focus on instead of stressing about the worst-case scenarios.”
Maria Lepowsky, 75, of Madison, Wisconsin, said the trial experience for her late husband Robert Brightman was similarly meaningful. Brightman participated in the trial for about two years as well.
“My husband believed in helping future patients,” she said, noting that in addition to extending his life, the drug also improved his quality of life.
“Inevitably, there were some serious side effects, but nonetheless, for most of the treatment period, he was able to take the 151 bus to Northwestern Medicine on his own to the clinic. That was really important to him to maintain his autonomy and be as close to normal a Chicago resident as you could be,” Lepowsky said.
How elraglusib works
Elraglusib was developed nearly 15 years ago inside Northwestern University labs. It targets a protein known as GSK-3 beta, which plays a role in tumor growth and suppression of the immune system.
Unlike traditional chemotherapy, which aims to kill cancer cells, elraglusib seems to act on the tumor microenvironment. That’s the mix of cancer cells, immune cells and surrounding tissue that can either support or weaken tumors.
Pancreatic tumors are hard to treat in part because of their microenvironment, which is particularly adept at suppressing immune response. In the study, patients who received elraglusib showed increases in cancer-fighting cells within their tumors, offering early evidence that the drug may help re-engage the immune system.
In addition, certain immune-related markers in the blood at the start of the trial were associated with longer survival among patients who received the drug. While these findings are preliminary, they suggest that elraglusib may be particularly effective in certain patients whose immune systems are already primed to respond.
Mahalingam and his colleagues are exploring a larger confirmatory phase 3 trial as funding and partnership allow. They are also interested in studying the drug in combination with other novel therapies to determine if broader clinical benefit can be achieved.
The other Northwestern co-author is Mary Mulcahy, MD, professor of Medicine in the Division of Hematology and Oncology.
The study was funded by Actuate Therapeutics.
Mahalingam receives institutional research funding from Actuate Therapeutics and has received compensation for consulting from Actuate Therapeutics. Northwestern has financial interests in Actuate Therapeutics.
https://news.feinberg.northwestern.edu/2026/04/14/new-drug-doubles-one-year-survival-in-pancreatic-cancer-trial/
GuruTrader
17年前
Actuate to Host Federal Executive Breakfast on Performance 2.0
Press Release
Source: Actuate Corporation
On Thursday October 1, 2009, 7:00 am EDT
Buzz up! 0 Print.Companies:Actuate Corp.
SAN MATEO, Calif.--(BUSINESS WIRE)--Actuate Corporation (NASDAQ:ACTU - News), the people behind BIRT™, today announced that it is hosting a complimentary Federal executive breakfast on achieving transparency and best practices in performance management within the government sector at the National Press Club in Washington, D.C. on October 7.
Related Quotes
Symbol Price Change
ACTU 5.77 0.00
{"s" : "actu","k" : "c10,l10,p20,t10","o" : "","j" : ""} Featured at the breakfast and discussing their performance management initiatives will be Jon Desenberg, policy director, Performance Institute and Janet W.L. Blanks, director, plans analysis and integration office, US Army Garrison, Fort Stewart and Hunter Army Airfield, Georgia.
The agenda for the Actuate hosted Federal executive breakfast includes the following:
8:00 - 8:30 a.m. : Networking Session
8:30 - 9:45 a.m. : Performance 2.0: From Measurement to Management
Jon Desenberg will lead a discussion of his latest work, lessons learned, and the promise of performance in a new age of transparency at all levels. Included in this discussion will be how dashboards, metrics and transparency have become mainstream topics in Federal government offices around the country.
9:45 - 10:00 a.m. : How to Improve Federal Decision Making with BIRT
In this session, Actuate representatives will explore the latest technology and business trends that will drive the next wave of performance management technologies with Web 2.0 Rich Information Applications.
10:00 - 11:00 a.m. : US Army Fort Stewart Measures Outcomes with BIRT Performance Scorecard
Janet W.L. Blanks will discuss how to perform a holistic approach to performance management in order to break through interagency silos and define realistic, achievable goals and objectives that are directly linked to the mission of the organization as well as their customers’ demands.
Federal Executive Breakfast Details:
Who: Federal Performance Management Experts from Federal Agencies and Actuate
What: Federal Executive Breakfast -- Performance 2.0
Where: National Press Club, Washington D.C.
529 14th St, NW
Washington, DC 20045
When:
October 7, 2009
To register and find our more details please visit: http://www.actuate.com/info/fedevent/
Actuate – the people behind BIRT
Actuate founded and continues to co-lead the Eclipse BIRT open source project. BIRT is the premier development environment for Rich Information Applications that present data in compelling and interactive ways via the web on any device. Actuate and its people are dedicated to making BIRT the best environment for our customers to develop Web 2.0 applications that drive revenue through higher customer satisfaction/loyalty and improve operational performance. The people of Actuate continually participate in and provide resources for the vibrant open source community that has emerged around BIRT. Anybody can participate in the BIRT movement by visiting www.birt-exchange.com.
Actuate offers value-add BIRT products and services that speed the development process and bring additional functionality, interactivity and enterprise scalability to BIRT-based Rich Information Applications. Actuate has over 4,400 customers globally in a diverse range of business areas including financial services and the public sector. Founded in 1993, Actuate is headquartered in San Mateo, California, with offices worldwide. Actuate is listed on NASDAQ under the symbol ACTU. For more information, visit the company's web site at www.actuate.com.
Copyright © 2009 Actuate Corporation. All rights reserved. Actuate and the Actuate logo are registered trademarks of Actuate Corporation and/or its affiliates in the U.S. and certain other countries. All other brands, names or trademarks mentioned may be trademarks of their respective owners.
Contact:
Actuate CorporationBen Hohmann, 650-645-3820 650-645-3820bhohmann@actuate.com
RjTrades™
18年前
7 Highly Rated Stocks on Sale
By Matt Koppenheffer February 27, 2008
7
Recommendations
I am always looking for a good deal. I buy extra boxes of Cocoa Puffs when they're on sale, and I pounce on undervalued stocks.
The idea that anybody would sell a stock for less than its worth might seem silly, but legendary value investor Ben Graham tells us, by way of allegory, how we can find these situations.
In The Intelligent Investor, Graham introduces readers to a wacky guy named Mr. Market. Mr. Market's game is to pay you house calls every day, and he offers to sell you interests in businesses he owns or to buy from you interests in businesses you own. Sometimes Mr. Market shows up at your door very excited, and offers you premium prices for your holdings. Other times he is inconsolably depressed about the future and will offer to sell you what he has for as low as pennies on the dollar.
So to find some of those stocks that make Mr. Market weepy, I turn once again to The Motley Fool's CAPS investor community. Each of the companies below had been given a five-star rating (the highest) by our community of investors just 30 days ago:
Stock
30-day Return
One-year Return
Current CAPS Rating
Sigma Designs (Nasdaq: SIGM)
(34.0%)
13.1%
****
Ceradyne (Nasdaq: CRDN)
(19.5%)
(30.7%)
*****
Hardinge (Nasdaq: HDNG)
(18.6%)
(43.1%)
*****
Actuate (Nasdaq: ACTU)
(18.6%)
(2.7%)
****
Gen-Probe (Nasdaq: GPRO)
(10.6%)
8.7%
****
China Security & Surveillance Technology (NYSE: CSR)
(9.2%)
0.0%
*****
ASML Holding (Nasdaq: ASML)
(8.7%)
(0.5%)
*****
Data from Motley Fool CAPS as of Feb. 26.
As the table shows, these stocks are all still highly regarded by the CAPS community despite their underperformance over the past month. These are not formal recommendations, but they could be a great place to kick off further research.
RjTrades™
18年前
Actuate Launches iServer Express to Meet the Report Deployment Needs of Eclipse BIRT Developers
Monday March 3, 7:00 am ET
iServer Express Deploys, Manages, Schedules, Secures, Runs and Shares BIRT and e.Spreadsheet Reports
SAN MATEO, Calif.--(BUSINESS WIRE)--Actuate Corporation (NASDAQ:ACTU - News), the leader in delivering Rich Internet Applications Without Limits™, today announced the launch of Actuate iServer Express, a full-featured report server for both Eclipse BIRT and e.Spreadsheet reports. iServer Express provides the report security, scheduling, management and distribution functionality that application users demand without the complexity of hand-coding. This off-the-shelf alternative retains the flexibility needed to easily integrate these features into any application environment. iServer Express is the latest in a series of Actuate initiatives to support the success of BIRT developers, building on already available resources including BIRT Exchange (http://www.birt-exchange.com), technical support, training and interactive reporting functionality.
iServer Express provides the following key services:
Easy installation: automated report delivery that can be up and running in less than 60 minutes
Security: secures reporting in a way that tailors to application user needs and fits with existing infrastructure
Scheduling and distribution: gives application users the reports they want, when and how they want them without needless burden on IT
Integration: gives developers complete control over the application user experience without sacrificing flexibility
iServer Express is built by an engineering team with 12 years of experience building enterprise-scale deployment services and leading-edge development tools, including BIRT. iServer Express includes a fully-documented Web Services API to replicate any function in any application, as well as a range of URL-based integration options. The product also has built-in security for granting permissions so that each user can only see the data and report components they are authorized to see, application developers can control user access via sheet, row or column-level permissions; and custom-render each report for a particular user. It includes a web-based scheduler, for use by anyone, with event- and time-based scheduling, job notification, parameter setting and a range of other options.
“For the past year, we’ve had a continual dialogue with BIRT users that contributed to an impressive two million plus downloads of BIRT. What we’re hearing is that a certain class of BIRT applications warrants off-the-shelf security and scheduling,” said Rich Guth, vice president and general manager, Java Group at Actuate. “I encourage developers to visit BIRT Exchange to review and download iServer Express for themselves, to evaluate whether the product can enhance their application.”
Visit BIRT Exchange to download a trial version of iServer Express as well as to explore documentation and discussion forums on the topic. Launched in September 2007, BIRT Exchange is already home to approximately 20,000 developers interested in BIRT reporting and spreadsheets in Java. The site is a place to share ideas, technical tips and code as well as a place to explore how to build reporting into applications. BIRT Exchange is now offering a new bi-monthly technical webinar series for Eclipse, BIRT, Java and report developers, the first of which will feature iServer Express (visit http://www.birt-exchange.com/iserverexpress/webinar for more information). This adds another resource to the existing forums, wiki, demos, downloads, documentation, BIRTing Out Loud blog and the popular DevShare portal.
Pricing and Availability
iServer Express is available immediately. A free download is available for trial evaluations. Pricing starts at $150 per user. For more information on iServer Express, please email sales@birt-exchange.com or visit http://www.birt-exchange.com.
Useful Links
iServer Express Linux free trial download: http://www.birt-exchange.com/iserverexpress/linuxdownload
iServer Express Windows free trial download: http://www.birt-exchange.com/iserverexpress/windownload
iServer Express discussion forum: http://www.birt-exchange.com/iserverexpress/forum
iServer Express demo: http://www.birt-exchange.com/iserverexpress/demo
Fully documented API: http://www.birt-exchange.com/iserverexpress/apidoc
iServer Express technical webinar: http://www.birt-exchange.com/iserverexpress/webinar
BIRTing out Loud blog: http://www.birt-exchange.com/modules/wordpress/
About Actuate Corporation
Actuate Corporation is dedicated to increasing the richness, interactivity and effectiveness of enterprise data, for everyone, everywhere. Actuate delivers the next generation RIA-ready information platform for both customer and employee-facing applications. The Actuate platform boasts unmatched scalability, high-performance, reliability and security. Its proven RIA capabilities and highly collaborative development architecture are backed by the world's largest open source information application developer community, grounded in BIRT, the Eclipse Foundation’s only top level Business Intelligence and reporting project.
Global 9000 organizations use Actuate to roll out RIA-enabled customer loyalty and Performance Management applications that improve customer satisfaction and employee productivity. The company has over 4,200 customers globally in a diverse range of business areas including financial services and the public sector, many of which have a long history of deploying Actuate-based solutions for dozens, or even hundreds of their mission-critical applications.
Founded in 1993, Actuate has headquarters in San Mateo, California, with offices worldwide. Actuate is listed on NASDAQ under the symbol ACTU. For more information on Actuate, visit the company's web site at www.actuate.com.
RjTrades™
18年前
Posting some news catching the board up
Actuate Named 2008 CODiE Awards Finalist for ''Best Business Intelligence Solution'' and ''Best Open Source Solution'' Categories
Wednesday February 27, 7:00 am ET
SAN MATEO, Calif.--(BUSINESS WIRE)--Actuate Corporation (NASDAQ:ACTU - News), the leader in delivering Rich Internet Applications Without Limits™, today announced that Actuate 9 has been selected as a finalist in the “Best Business Intelligence Solution” and “Best Open Source Solution” categories in the 2008 Software & Information Industry Association’s (SIIA) CODiE Awards.
ADVERTISEMENT
The CODiE Awards program recognizes outstanding achievement in the software and information industry. This year’s edition was very competitive with over 1,100 nominees in 68 categories. “Competition is tough this year and that makes selection as a CODiE Finalist a real achievement,” said Ken Wasch, SIIA president. “All the companies on this year’s list should feel justifiably proud of their recognition.”
Actuate 9, released in August 2007, is the only platform that meets the entire range of reporting requirements from pixel-perfect reporting, ad hoc query and web-based collaborative reporting to spreadsheet and analytics reporting. In addition, Actuate 9 introduced interface and performance improvements that allow for faster, more cost-effective and widespread deployments of reporting applications. Actuate 9, which is largely based on open source technology, has been recognized as a best-of-breed Business Intelligence tool by several industry-leading publications and organizations. The Actuate sponsored Eclipse Business Intelligence Reporting Tool (BIRT) project is the foundation of Actuate 9. BIRT is a community-driven, platform-neutral project that allows developers to create highly visual web reports, dashboards and ad-hoc report templates, delivered to users via a web browser. For more information on BIRT and Actuate's BIRT Exchange community site, please visit http://www.birt-exchange.com.
“We’re thrilled about being a finalist for the CODiE Awards,” said Nobby Akiha, SVP of marketing at Actuate. “This recognition is a testament to our commitment to deliver our customers enterprise solutions customized to meet their needs. As organizations demand more efficient and productive collaborative reporting applications, it’s gratifying when solutions like Actuate 9 obtain recognition from leading organizations such as the SIIA.”
The 23rd Annual CODiE Awards Gala will be held on May 20, 2008 at the Palace Hotel, San Francisco, CA, where winners will be formally announced. To access a complete list of 2008 CODiE Awards finalists, please visit: http://www.siia.net/codies/2008/finalists.asp.
About Actuate Corporation
Actuate Corporation is dedicated to increasing the richness, interactivity and effectiveness of enterprise data, for everyone, everywhere. Actuate delivers the next generation RIA-ready information platform for both customer and employee-facing applications. The Actuate platform boasts unmatched scalability, high-performance, reliability and security. Its proven RIA capabilities and highly collaborative development architecture are backed by the world’s largest open source information application developer community, grounded in BIRT, the Eclipse Foundation’s only top level Business Intelligence and reporting project.
Global 9000 organizations use Actuate to roll out RIA-enabled customer loyalty and Performance Management applications that improve customer satisfaction and employee productivity. The company has over 4,200 customers globally in a diverse range of business areas including financial services and the public sector, many of which have a long history of deploying Actuate-based solutions for dozens, or even hundreds of their mission-critical applications. Founded in 1993, Actuate has headquarters in San Mateo, California, with offices worldwide. Actuate is listed on NASDAQ under the symbol ACTU. For more information on Actuate, visit the company’s web site at www.actuate.com.
riksea
18年前
News out Feb. 4, 2008 Here it is!!!
February 4, 2008 - 6:44 PM EST
Actuate Steps-Up Stock Repurchase Program
Board Authorizes Increase of Over 50% for the First Quarter
Actuate Corporation (NASDAQ:ACTU), the leader in delivering Rich Internet Applications Without Limits™, today announced that its Board of Directors authorized the increase of its existing stock repurchase program by over 50% for the first quarter of fiscal year 2008.
“Actuate’s Board of Directors believes that repurchasing shares of our stock at the current market price is a great use of capital,” said Pete Cittadini, Actuate's president and CEO. “This increased authorization exhibits the high level of confidence the Board of Directors has in the long-term prospects of the company and our Open Source initiative.”
About Actuate Corporation
Actuate Corporation is dedicated to increasing the richness, interactivity, and effectiveness of enterprise data, for everyone, everywhere. Actuate delivers the next generation RIA-ready information platform for both customer and employee-facing applications. The Actuate platform boasts unmatched scalability, high-performance, reliability and security. Its proven RIA capabilities and highly collaborative development architecture are backed by the world’s largest open source information application developer community, grounded in BIRT, the Eclipse Foundations’ only top level Business Intelligence and reporting project.
Global 9000 organizations use Actuate to roll out RIA-enabled customer loyalty and Performance Management applications that improve customer satisfaction and employee productivity. The company has over 4,200 customers globally in a diverse range of business areas including financial services and the public sector, many of which have a long history of deploying Actuate-based solutions for dozens, or even hundreds of their mission-critical applications. Founded in 1993, Actuate has headquarters in San Mateo, California, with offices worldwide. Actuate is listed on NASDAQ under the symbol ACTU. For more information on Actuate, visit the company’s web site at www.actuate.com.
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Minddoc7
18年前
surf1944
20年前
メールアドレスで登録
